Mesoblast Limited (MSB.AX)
AUD 3.05
(54.04%)
AUD 3.05
(54.04%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 | 5.9 Million USD | -21.32% |
| 2023 | 7.5 Million USD | -26.54% |
| 2022 | 10.21 Million USD | 36.95% |
| 2021 | 7.45 Million USD | -76.81% |
| 2020 | 32.15 Million USD | 92.3% |
| 2019 | 16.72 Million USD | -3.57% |
| 2018 | 17.34 Million USD | 618.95% |
| 2017 | 2.41 Million USD | -94.33% |
| 2016 | 42.54 Million USD | 79.16% |
| 2015 | 23.74 Million USD | -8.59% |
| 2014 | 25.98 Million USD | -9.75% |
| 2013 | 28.78 Million USD | -24.8% |
| 2012 | 38.27 Million USD | -68.34% |
| 2011 | 120.92 Million USD | 2198468.82% |
| 2010 | 5500.00 USD | -99.38% |
| 2009 | 890.7 Thousand USD | -2.1% |
| 2008 | 909.8 Thousand USD | -45.82% |
| 2007 | 1.67 Million USD | -40.49% |
| 2006 | 2.82 Million USD | 461.11% |
| 2005 | 502.88 Thousand USD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 1.69 Million USD | 0.0% |
| 2024 Q1 | 1.69 Million USD | -20.8% |
| 2024 FY | 5.9 Million USD | -21.32% |
| 2023 Q3 | 1.93 Million USD | -2.07% |
| 2023 Q4 | 2.13 Million USD | 10.31% |
| 2023 Q1 | 1.44 Million USD | -35.12% |
| 2023 Q2 | 1.98 Million USD | 37.21% |
| 2023 FY | 7.5 Million USD | -26.54% |
| 2022 Q4 | 2.22 Million USD | 10.59% |
| 2022 Q3 | 2.01 Million USD | -15.58% |
| 2022 Q2 | 2.38 Million USD | -33.72% |
| 2022 FY | 10.21 Million USD | 36.95% |
| 2022 Q1 | 3.59 Million USD | 80.06% |
| 2021 Q4 | 1.99 Million USD | 4.34% |
| 2021 Q2 | 2.23 Million USD | 73.47% |
| 2021 Q1 | 1.28 Million USD | 86.27% |
| 2021 Q3 | 1.91 Million USD | -14.45% |
| 2021 FY | 7.45 Million USD | -76.81% |
| 2020 Q3 | 12.08 Million USD | 513.56% |
| 2020 Q4 | 692 Thousand USD | -94.27% |
| 2020 FY | 32.15 Million USD | 92.3% |
| 2020 Q2 | 1.96 Million USD | -88.33% |
| 2020 Q1 | 16.87 Million USD | 757.75% |
| 2019 Q2 | 1.87 Million USD | -83.93% |
| 2019 FY | 16.72 Million USD | -3.57% |
| 2019 Q3 | 1.24 Million USD | -33.21% |
| 2019 Q4 | 1.96 Million USD | 57.49% |
| 2019 Q1 | 11.63 Million USD | 584.53% |
| 2018 Q3 | 991 Thousand USD | -92.54% |
| 2018 FY | 17.34 Million USD | 618.95% |
| 2018 Q4 | 1.7 Million USD | 71.54% |
| 2018 Q2 | 13.28 Million USD | 1031.43% |
| 2018 Q1 | 1.17 Million USD | 107.42% |
| 2017 FY | 2.41 Million USD | -94.33% |
| 2017 Q1 | 395 Thousand USD | -98.53% |
| 2017 Q2 | 550 Thousand USD | 39.24% |
| 2017 Q3 | 901 Thousand USD | 63.82% |
| 2017 Q4 | 566 Thousand USD | -37.18% |
| 2016 FY | 42.54 Million USD | 79.16% |
| 2016 Q1 | 7.51 Million USD | -7.96% |
| 2016 Q2 | 4.01 Million USD | -46.57% |
| 2016 Q4 | 26.87 Million USD | 548.94% |
| 2016 Q3 | 4.14 Million USD | 3.19% |
| 2015 Q3 | 4.24 Million USD | -3.08% |
| 2015 FY | 23.74 Million USD | -8.59% |
| 2015 Q4 | 8.16 Million USD | 92.43% |
| 2015 Q2 | 4.37 Million USD | -37.18% |
| 2015 Q1 | 6.96 Million USD | 190.47% |
| 2014 Q3 | 2.55 Million USD | -59.36% |
| 2014 Q4 | 2.39 Million USD | -6.14% |
| 2014 FY | 25.98 Million USD | -9.75% |
| 2014 Q1 | 11.85 Million USD | 29.67% |
| 2014 Q2 | 6.28 Million USD | -46.97% |
| 2013 Q2 | 7.64 Million USD | 0.06% |
| 2013 Q4 | 9.14 Million USD | -12.05% |
| 2013 Q3 | 10.39 Million USD | 35.92% |
| 2013 FY | 28.78 Million USD | -24.8% |
| 2013 Q1 | 7.64 Million USD | 0.0% |
| 2012 FY | 38.27 Million USD | -68.34% |
| 2011 FY | 120.92 Million USD | 2198468.82% |
| 2010 FY | 5500.00 USD | -99.38% |
| 2009 FY | 890.7 Thousand USD | -2.1% |
| 2008 FY | 909.8 Thousand USD | -45.82% |
| 2007 FY | 1.67 Million USD | -40.49% |
| 2006 FY | 2.82 Million USD | 461.11% |
| 2005 FY | 502.88 Thousand USD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| EZZ Life Science Holdings Limited | 66.44 Million AUD | 91.117% |
| Anatara Lifesciences Ltd | - AUD | -Infinity% |
| Bio-Gene Technology Limited | 18.32 Thousand AUD | -32116.157% |
| Zelira Therapeutics Limited | 94.95 Thousand AUD | -6115.772% |
| Biome Australia Limited | 13 Million AUD | 54.631% |
| Patrys Limited | 1.39 Million AUD | -323.336% |
| Orthocell Limited | 5.31 Million AUD | -11.036% |
| Imugene Limited | - AUD | -Infinity% |
| Noxopharm Limited | 2.4 Million AUD | -145.888% |
| PYC Therapeutics Limited | 22.05 Million AUD | 73.245% |
| Chimeric Therapeutics Limited | 7.45 Million AUD | 20.86% |
| Prescient Therapeutics Limited | 3.71 Million AUD | -58.982% |
| Proteomics International Laboratories Limited | 892.14 Thousand AUD | -561.553% |
| Cynata Therapeutics Limited | 2.31 Million AUD | -154.875% |
| CSL Limited | 22.41 Billion AUD | 99.974% |
| Arovella Therapeutics Limited | 17 Thousand AUD | -34617.647% |
| Botanix Pharmaceuticals Limited | 601.82 Thousand AUD | -880.692% |
| Race Oncology Limited | 4 Million AUD | -47.422% |
| Clinuvel Pharmaceuticals Limited | 88.17 Million AUD | 93.307% |
| Starpharma Holdings Limited | 8.28 Million AUD | 28.797% |
| Nanollose Limited | 12.5 Thousand AUD | -47112.223% |
| Memphasys Limited | 60 Thousand AUD | -9736.667% |
| Invex Therapeutics Ltd | 1.21 Million AUD | -386.861% |
| NeuroScientific Biopharmaceuticals Limited | - AUD | -Infinity% |
| Amplia Therapeutics Limited | 4.45 Million AUD | -32.548% |
| Island Pharmaceuticals Limited | 1.25 Million AUD | -371.566% |
| Nyrada Inc. | - AUD | -Infinity% |
| Clarity Pharmaceuticals Ltd | 11.5 Million AUD | 48.708% |
| Telix Pharmaceuticals Limited | 496.65 Million AUD | 98.812% |
| Dimerix Limited | 583.47 Thousand AUD | -911.521% |
| Neuren Pharmaceuticals Limited | 231.92 Million AUD | 97.455% |
| PharmAust Limited | - AUD | -Infinity% |
| Immutep Limited | 3.5 Million AUD | -68.353% |
| BTC Health Limited | 16.36 Thousand AUD | -35975.795% |
| Acrux Limited | 5.09 Million AUD | -15.93% |
| Alterity Therapeutics Limited | 4.01 Million AUD | -46.842% |
| Biotron Limited | - AUD | -Infinity% |
| Radiopharm Theranostics Limited | 299.22 Thousand AUD | -1872.409% |
| Tissue Repair Ltd | 152.24 Thousand AUD | -3776.774% |
| AdAlta Limited | 1.73 Million AUD | -239.625% |
| Hexima Limited | - AUD | -Infinity% |
| AnteoTech Limited | 460.39 Thousand AUD | -1181.937% |
| Paradigm Biopharmaceuticals Limited | 65.8 Thousand AUD | -8869.605% |
| Recce Pharmaceuticals Ltd | - AUD | -Infinity% |
| Avecho Biotechnology Limited | 473.55 Thousand AUD | -1146.328% |
| Actinogen Medical Limited | 9.93 Million AUD | 40.573% |
| Immuron Limited | 4.9 Million AUD | -20.379% |
| Argenica Therapeutics Limited | 2.59 Million AUD | -127.18% |